<DOC>
	<DOC>NCT01112306</DOC>
	<brief_summary>Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)</brief_summary>
	<brief_title>ACT-293987 in Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Patients who participated to the doubleblind study AC065A302 and either had a morbidity event or had completed the study as scheduled per protocol. Signed informed consent. Patients who have started receiving prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) since the last study drug intake in AC065A302/GRIPHON. Severe hepatic impairment (ChildPugh C). Females who are pregnant or who plan to become pregnant during the study, or are breastfeeding. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Open-label</keyword>
	<keyword>PAH</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>